Search

Influenza A virus A/Darwin/6/2021 IVR-227 (H3N2) antigen (propiolactone inactivated)

These vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which results in an immunological defense against future exposure to the virus, or "antigen … Upon re-exposure to an influenza virus, the immune system is prepared with circulating antibodies that identify and destroy the virus.

Glafenine

An anthranilic acid derivative with analgesic properties used for the relief of all types of pain. Glafenine is withdrawn from the American market.

Chromous sulfate

VT-111

VT-111 is a 55 kDa secreted glycoprotein belonging to a superfamily of proteins called SERPINS, which share a general structure and mechanism for proteinase inhibition.

Talizumab

TNX-901 is a therapeutic monoclonal antibodies designed to address significant unmet medical needs in the areas of asthma, allergy, inflammation and other diseases affecting the human immune system.

Paramethasone

It has been used by mouth in the treatment of all conditions in which corticosteroid therapy is indicated except adrenal-deficiency states for which its lack of sodium-retaining properties makes it less

Carbon black

Produced by the incomplete combustion of hydrocarbons, carbon black is an insoluble pigment [A263396] with demonstrated adverse effects on pulmonary function. … [A263401] Upon inhalation, carbon black has been reported to trigger an inflammatory response in the lung tissue [A263401] and has been linked to carcinogenicity.[A263406, A263411, A263416]

Darifenacin

This block reduces the urgency to urinate and so it should not be used in people with urinary retention. … It is unknown if M3 receptor selectivity is clinically advantageous in overactive bladder syndrome treatments.

Vibostolimab

Vibostolimab is under investigation in clinical trial NCT04303169 (Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With … Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02)).

iCo-007

) such as age-related macular degeneration (AMD) and diabetic retinopathy(DR). … iCo-007 (formerly known as ISIS 13650) is a second generation antisense compound being developed by iCo for the treatment of various eye diseases caused by the formation of new blood vessels (angiogenesis